

## [Vincristine](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01CA02](#)

EMLc

Indication

Malignant neoplasms of kidney, except renal pelvis ICD11 code: [2D40.Z](#)

INN

Vincristine

Medicine type

Chemical agent

List type

Complementary

Formulations

**Parenteral > General injections > IV:** 1 mg in vial (vincristine sulfate) ; 5 mg in vial (vincristine sulfate) ; 1 mg per mL in vial (vincristine sulfate) ; 2 mg per 2 mL in vial (vincristine sulfate)

EML status history

First added in 2011 ([TRS 965](#))

Changed in 2015 ([TRS 994](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Vincristine](#)

[DrugBank](#)

[Vincristine](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.